4-(2,4-dichloro-benzyloxy)-3-(1-imidazol-1-yl-butyl)-aniline | 71289-61-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(2,4-dichloro-benzyloxy)-3-(1-imidazol-1-yl-butyl)-aniline
• 英文别名: {4-amino-2-[1-(1-imidazolyl)-butyl]-phenyl}-(2,4-dichlorobenzyl)ether；4-[(2,4-Dichlorophenyl)methoxy]-3-(1-imidazol-1-ylbutyl)aniline
• CAS: 71289-61-7
• 化学式: C₂₀H₂₁Cl₂N₃O
• 分子量: 390.312
• InChiKey: IEASHUXECSOQFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Aromatase inhibition to enhance assisted reproduction
  申请人：——

  公开号：US20040204393A1

  公开（公告）日：2004-10-14

  The use of at least one aromatase inhibitor in the production of a medicament for improving the implantation and pregnancy rates for a female undergoing assisted reproduction treatment, which comprises one or more daily doses of an aromatase inhibitor (AI) for administration during assisted reproduction cycles or ovarian stimulation cycles, wherein the doses of AI are selected from amounts effective to reduce serum estradiol levels. Also disclosed are related pharmaceutical preparations and packages.

  使用至少一种芳香化酶抑制剂生产一种药物，用于提高接受辅助生殖治疗的女性的着床率和妊娠率，该药物包括一种或多种每日剂量的芳香化酶抑制剂（AI），用于在辅助生殖周期或卵巢刺激周期期间给药，其中AI的剂量选自有效降低血清雌二醇水平的量。还公开了相关的药物制剂和包装。
• Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
  申请人：——

  公开号：US20040235812A1

  公开（公告）日：2004-11-25

  A pharmaceutical preparation for males for increasing physiologic endogenous testosterone comprising at least one aromatase inhbitor and an estrogen and methods of use thereof for increasing male libido are provided.

  本研究提供了一种用于增加男性生理性内源性睾酮的药物制剂，该制剂包含至少一种芳香化酶抑制剂和一种雌激素，并提供了增加男性性欲的使用方法。
• Combination of an aromatase inhibitor with a bisphosphonate
  申请人：Bhatnagar S Ajay

  公开号：US20060069067A1

  公开（公告）日：2006-03-30

  The present invention provides a combination for the treatment of a disease or condition which responds to aromatase inhibition, in particular a proliferative disease, especially a malignant disease such as breast cancer or similar soft tissue endocrine-sensitive cancer, most preferably breast cancer, comprising an aromatase inhibitor and a bisphosphonate for simultaneous, concurrent, separate or sequential use in the prevention of bone loss which is caused by the treatment with an aromatase inhibitor. Also provided is a method of treating a patient suffering from a disease or condition which responds to aromatase inhibition comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an aromatase inhibitor.

  本发明提供了一种组合物，用于治疗对芳香化酶抑制剂有反应的疾病或病症，特别是增殖性疾病，尤其是恶性疾病，如乳腺癌或类似的软组织内分泌敏感性癌症，最优选乳腺癌，该组合物包括芳香化酶抑制剂和双膦酸盐，用于同时、并发、单独或连续使用，以防止因芳香化酶抑制剂治疗而引起的骨质流失。还提供了一种治疗对芳香化酶抑制剂有反应的疾病或病症患者的方法，包括向患者施用有效量的双膦酸盐和有效量的芳香化酶抑制剂。
• Use of Aromatase Inhibitors for Treatment of Ectopic Pregnancy
  申请人：Mitwally F. M. Mohamed

  公开号：US20080025991A1

  公开（公告）日：2008-01-31

  Following a diagnosis of ectopic pregnancy, at least one aromatase inhibitor, is administered to a patient, either alone or in combination with other aromatase inhibitors or therapeutic agents or as an adjuvant to conservative surgical treatment, such as laparoscopy, to prevent the establishment and/or continuation of the ectopic pregnancy. In certain preferred embodiments, the aromatase inhibitor is administered in conjunction with methotrexate.
• Use of Aromatase Inhibitors for Endometrial Thinning in Preparation for Surgical Procedures on the Endometrial Cavity and Uterus
  申请人：Mitwally F.M. Mohamed

  公开号：US20080045484A1

  公开（公告）日：2008-02-21

  Aromatase inhibitors are administered to a female patient prior to endometrial ablation or resection procedures in order to thin the endometrium to a thickness of less than 6 mm, and preferably less than 4 mm, so as to enhance the treatment outcome. Of course, administration of aromatase inhibitors would be useful for other surgical procedures on the endometrial cavity and the uterus. Commercially available aromatase inhibitors, including, the nonsteroidal preparations, anastrozole and letrozole, and a steroidal agent, exemestane, are well-tolerated, and have been shown to decrease serum estrogen levels. The aromatase inhibitor can be used alone, or in combination with other aromatase inhibitors or pharmaceutical agents, such as hormones.